Overview

This trial is active, not recruiting.

Condition polycystic ovary syndrome
Treatments metformin er, metformin
Sponsor Massachusetts General Hospital
Collaborator American Diabetes Association
Start date June 2011
End date October 2016
Trial size 200 participants
Trial identifier NCT01389778, 2010-P-002945

Summary

Polycystic ovary syndrome (PCOS) is the most common endocrine disorder in reproductive age women. Women with PCOS have a high risk of prediabetes, type 2 diabetes and heart disease. The investigators have found a possible change in the DNA (genes of the body that encode all of our traits) that seems to be related to insulin resistance. In this study, the investigators will try to determine whether the change in the gene affects a woman's ability to respond to a common treatment for PCOS, metformin.

These studies will uncover the change in a gene that might be one of the causes of PCOS. Discovering this gene will help better understand the diabetes and insulin abnormalities that are common in PCOS and will help us to better diagnose and treat PCOS to prevent the diabetes in these women.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Endpoint classification efficacy study
Intervention model single group assignment
Masking open label
Primary purpose treatment
Arm
(Experimental)
Subjects treated with metformin.
metformin er
Metformin ER 1500 mg for 12 weeks
metformin

Primary Outcomes

Measure
Insulin Sensitivity
time frame: 3 months

Secondary Outcomes

Measure
Androgen Levels
time frame: 3 months
Ovulatory Rate
time frame: 3 months

Eligibility Criteria

Female participants from 18 years up to 40 years old.

Inclusion Criteria: - Polycystic ovary syndrome - No medications for 1 month - Good general health Exclusion Criteria: - Smoker - Acute infection or chronic disease - Diabetes - Trying to get pregnant - Bleeding disorders

Additional Information

Official title Polycystic Ovary Syndrome Genetics and Treatment Response
Description Polycystic ovary syndrome (PCOS), which affects 7-10% of reproductive aged women, has traditionally been classified as a reproductive and dermatologic syndrome because of its high rate of infertility and the cosmetic complications of hyperandrogenism. However, it has become increasingly clear that insulin resistance is important in the pathogenesis of the disorder. There are a number of variants that have been determined to be associated with PCOS risk. The investigators will determine the effect of these variants on the phenotype and response to treatment in PCOS. Subjects with PCOS will undergo extensive phenotyping including adipose tissue biopsy, dual energy X-ray absorptiometry (DXA, bone density) scan to examine adipose stores, an intravenous glucose tolerance test to study insulin sensitivity and beta cell function, androgen stimulation and inflammatory markers. The phenotyping will be repeated after 3 months of treatment with metformin. The studies will determine whether the genotype at PCOS risk variants dictates phenotype and response to treatment with metformin. Discovering genes involved in the etiology of PCOS will help pull us out of the endless circle that has characterized our understanding of PCOS pathophysiology for many years. The proposal also has the potential to illuminate one etiology of insulin resistance, which is present even in lean women with PCOS, and the impaired glucose tolerance and diabetes found in over 40% of PCOS patients.
Trial information was received from ClinicalTrials.gov and was last updated in October 2015.
Information provided to ClinicalTrials.gov by Massachusetts General Hospital.